Treatment of malignant ascites with a second cycle of catumaxomab in gastric signet cell carcinoma - A report of 2 cases

Oncology Research and Treatment

Volumn 37, Issue 11, 2014, Pages 674-677

  Thomaidis, Thomas ^a   Wörns, Marcus A ^a   Galle, Peter R ^a   Möhler, Markus ^a   Schattenberg, Jörn M ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

Catumaxomab; Malignant ascites; Repeated treatment; Signet cell gastric cancer

Indexed keywords

C REACTIVE PROTEIN; CATUMAXOMAB; DOCETAXEL; EPITHELIAL CELL ADHESION MOLECULE; OXALIPLATIN; UFT; BISPECIFIC ANTIBODY;

ABDOMINAL DRAINAGE; ABDOMINAL PAIN; ADULT; ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER SURGERY; CARCINOMATOUS PERITONITIS; CASE REPORT; DEATH; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ESOPHAGOJEJUNOSTOMY; FEMALE; GASTRECTOMY; HAND FOOT SYNDROME; HUMAN; HUMAN CELL; INFLAMMATION; INTRAOPERATIVE PERIOD; KIDNEY DYSFUNCTION; KIDNEY FAILURE; LEUKOCYTOSIS; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MALE; MALIGNANT ASCITES; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; PARACENTESIS; PERITONEUM METASTASIS; ROUX Y ANASTOMOSIS; STOMACH CARCINOMA; TACHYCARDIA; ASCITES; CARCINOMA, SIGNET RING CELL; PARENTERAL DRUG ADMINISTRATION; PERITONEAL NEOPLASMS; RETREATMENT; STOMACH NEOPLASMS;

ANTIBODIES, BISPECIFIC; ASCITES; CARCINOMA, SIGNET RING CELL; FEMALE; HUMANS; INFUSIONS, PARENTERAL; MALE; MIDDLE AGED; PERITONEAL NEOPLASMS; RETREATMENT; STOMACH NEOPLASMS;

EID: 84913534464     PISSN: 22965270     EISSN: 22965262     Source Type: Journal    
DOI: 10.1159/000365597     Document Type: Article

References (13)

1. Runyon BA: Care of patients with ascites. N Engl J Med 1994;330:337-342.
2. Ayantunde AA, Parsons SL: Pattern and prognostic factors in patients with malignant ascites: a retrospective study. Ann Oncol 2007;18:945-949.
3. Sugarbaker PH, Yu W, Yonemura Y: Gastrectomy, peritonectomy, and perioperative intraperitoneal chemotherapy: the evolution of treatment strategies for advanced gastric cancer. Semin Surg Oncol 2003;21:233-248.
4. Wimberger P, Gilet H, Gonschior AK, Heiss MM, Moehler M, Oskay-Oezcelik G, Al-Batran SE, Schmalfeldt B, Schmittel A, Schulze E, Parsons SL: Deterioration in quality of life (QoL) in patients with malignant ascites: results from a phase II/III study comparing paracentesis plus catumaxomab with paracentesis alone. Ann Oncol 2012;23:1979-1985.
5. Roviello F, Marrelli D, Neri A, Cerretani D, de Manzoni G, Pedrazzani C, Cioppa T, Nastri G, Giorgi G, Pinto E: Treatment of peritoneal carcinomatosis by cytoreductive surgery and intraperitoneal hyperthermic chemoperfusion (IHCP): postoperative outcome and risk factors for morbidity. World J Surg 2006;30:2033-2040; discussion 2041-2032.
6. Heiss MM, Murawa P, Koralewski P, Kutarska E, Kolesnik OO, Ivanchenko VV, Dudnichenko AS, Aleknaviciene B, Razbadauskas A, Gore M, Ganea-Motan E, Ciuleanu T, Wimberger P, Schmittel A, Schmalfeldt B, Burges A, Bokemeyer C, Lindhofer H, Lahr A, Parsons SL: The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II/III trial. Int J Cancer 2010;127:2209-2221.
7. Sehouli J, Wimberger P, Vergote IB, Rosenberg P, Schneeweiss A, Bokemeyer C, Salat C, Scambia G, Berton-Rigaud D, Siena S, Santoro A, Cervantes-Ruiperez A, Guastalla J, Tournigand C, Colombo N, Dudnitchenko A, Bondar V, Westermann AM, Lordick F: Catumaxomab with and without prednisolone in patients with malignant ascites due to epithelial cancer: results from the phase IIIb CASIMAS study. J Clin Oncol 2012;30:e13097.
8. Pietzner K, Vergote I, Santoro A, Marme F, Rosenberg P, Friccius-Quecke H, Sehouli J: Results of a phase II clinical trial to evaluate a re-challenge of intraperitoneal catumaxomab for treatment of malignant ascites (MA) due to epithelial cancer (SECIMAS). J Clin Oncol 2013;31(suppl):abstr 5582.
9. Ott MG, Marme F, Moldenhauer G, Lindhofer H, Hennig M, Spannagl R, Essing MM, Linke R, Seimetz D: Humoral response to catumaxomab correlates with clinical outcome: results of the pivo tal phase II/III study in patients with malignant ascites. Int J Cancer 2012;130:2195-2203.
10. Pietzner K, Jager M, Schoberth A, Oskay-Ozcelik G, Kuhberg M, Lindhofer H, Sehouli J: First patient treated with a re-challenge of catumaxomab in recurrent malignant ascites: a case report. Med Oncol 2012;29:1391-1396.
11. Petrelli F, Borgonovo K, Lonati V, Elia S, Barni S: Regression of liver metastases after treatment with intraperitoneal catumaxomab for malignant ascites due to breast cancer. Target Oncol 2013;8:291-294
12. Woopen H, Pietzner K, Darb-Esfahani S, Oskay-Oezcelik G, Sehouli J: Extraperitoneal response to intraperitoneal immunotherapy with catumaxomab in a patient with cutaneous lymphangiosis carcinomatosa from ovarian cancer: a case report and review of the literature. Med Oncol 2012;29:3416-3420.
13. Moehler M, Sieben M, Roth S, Springsguth F, Leuchs B, Zeidler M, Dinsart C, Rommelaere J, Galle PR: Activation of the human immune system by chemotherapeutic or targeted agents combined with the oncolytic parvovirus h-1. BMC Cancer 2011;11:464.